455 related articles for article (PubMed ID: 26197085)
1. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
[TBL] [Abstract][Full Text] [Related]
2. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
3. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
Saljoughian N; Taheri T; Zahedifard F; Taslimi Y; Doustdari F; Bolhassani A; Doroud D; Azizi H; Heidari K; Vasei M; Namvar Asl N; Papadopoulou B; Rafati S
PLoS Negl Trop Dis; 2013; 7(4):e2174. PubMed ID: 23638195
[TBL] [Abstract][Full Text] [Related]
4. Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.
Shahbazi M; Zahedifard F; Saljoughian N; Doroud D; Jamshidi S; Mahdavi N; Shirian S; Daneshbod Y; Hamid Zarkesh-Esfahani S; Papadopoulou B; Rafati S
Vet Parasitol; 2015 Sep; 212(3-4):130-9. PubMed ID: 26255093
[TBL] [Abstract][Full Text] [Related]
5. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
6. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
[TBL] [Abstract][Full Text] [Related]
7. Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs.
Fiuza JA; Santiago Hda C; Selvapandiyan A; Gannavaram S; Ricci ND; Bueno LL; Bartholomeu DC; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2013 Apr; 31(14):1785-92. PubMed ID: 23398933
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
[TBL] [Abstract][Full Text] [Related]
11. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
13. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.
Fernandes AP; Costa MM; Coelho EA; Michalick MS; de Freitas E; Melo MN; Luiz Tafuri W; Resende Dde M; Hermont V; Abrantes Cde F; Gazzinelli RT
Vaccine; 2008 Oct; 26(46):5888-95. PubMed ID: 18786587
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
[TBL] [Abstract][Full Text] [Related]
15. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
[TBL] [Abstract][Full Text] [Related]
17. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
[TBL] [Abstract][Full Text] [Related]
19. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.
Roatt BM; Aguiar-Soares RD; Vitoriano-Souza J; Coura-Vital W; Braga SL; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; de Lana M; Figueiredo Gontijo N; Marques MJ; Giunchetti RC; Reis AB
PLoS One; 2012; 7(11):e49780. PubMed ID: 23189161
[TBL] [Abstract][Full Text] [Related]
20. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil.
Regina-Silva S; Feres AM; França-Silva JC; Dias ES; Michalsky ÉM; de Andrade HM; Coelho EA; Ribeiro GM; Fernandes AP; Machado-Coelho GL
Vaccine; 2016 Apr; 34(19):2233-9. PubMed ID: 26997002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]